Are tick-borne encephalitis vaccines interchangeable?

Expert Review of Vaccines

Volumn 5, Issue 4, 2006, Pages 461-466

  Bröker, Michael ^a   Schöndorf, Ines ^a  

^a Clinical Research and Medical Affairs   (Germany)

Author keywords

Booster vaccination; Immune response; Interchangeability; Primary immunization course; Tick borne encephalitis

Indexed keywords

ADJUVANT; FSME VAKZINE BEHRING; POLYGELINE; THIOMERSAL; TICK BORNE ENCEPHALITIS VACCINE; TICOVAC;

CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG SUBSTITUTION; HUMAN; IMMUNIZATION; IMMUNOGENICITY; PRIORITY JOURNAL; REVIEW; TICK BORNE ENCEPHALITIS; TREATMENT RESPONSE; VIRUS GENOME; VIRUS STRAIN;

ENCEPHALITIS VIRUSES; ENCEPHALITIS, TICK-BORNE; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; JAPANESE ENCEPHALITIS VACCINES; VACCINES, INACTIVATED; VIRAL VACCINES;

EID: 33750296510     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.5.4.461     Document Type: Review

References (15)

1. Dumpis U, Crook D, Oksi J. Tick-borne encephalitis. Clin. Infect. Dis. 28, 882-890 (1999).
2. Löw-Baselli A, Pöllabauer EM, Fritsch A et al. FSME-Immun® - new clinical data on rapid immunization. Ellipse 20, 32-33 (2004).
3. Löw-Baselli A, Pöllabauer EM, Fritsch S et al. Immunogenicity and safety of FSME-Immun® 0.5 ml using a rapid immunization schedule. Proceedings of the VIII International Potsdam Symposium on Tick-Borne Diseases (IPS-VIII), Jena, Germany, 10-12 March (2005).
4. Zent O, Bröker M. Tick-borne encephalitis vaccines: past and present. Expert Rev. Vaccines 4, 747-755 (2005).
5. Barrett PN, Schober-Bendixen S, Ehrlich HJ. History of TBE vaccines. Vaccine 21(Suppl. 1), 41-49 (2003).
6. Zent O, Hennig R, Banzhoff A, Bröker M. Protection against tick-borne encephalitis (TBE) with a new vaccine formulation - free of protein-derived stabilizers. J. Travel Med. 12, 85-93 (2005).
7. Ecker M, Allison S, Meixner T, Heinz F. Sequence analysis and genetic classification of tick-borne encephalitis viruses from Europe and Asia. J. Gen. Virol. 80, 179-185 (1999).
8. Behringwerke AG. Clinical study BI71.061/7MN-304IP, data on file (1991).
9. Pazdiora P, Januska J. Dynamika tvorby protilatek po ockovani proti klistove encefalitide. Dynamics of antibody formation after vaccination against tick born encephalitis. Epidemiol. Mikrobiol. Imunol. 53, 17-21 (2004).
10. Rendi-Wagner P, Kundi M, Zent O et al. Immunogenicity and safety of a booster vaccination against tick-borne encephalitis more than 3 years following the last immunisation. Vaccine 23, 427-434 (2004).
11. Loew-Baselli A, Fritsch S, Pavlova BG et al. Safety and immunogenicity of FSME-Immun® 'new' vs. Encepur® in adults. Int. J. Med. Microbiol. 293(Suppl. 37), 128-129 (2004).
12. Summeries of Product Charcteristics, Encepur®. Fachinfo-Service Germany, March (2005).
13. Summeries of Product Charcteristics, FSME-Immun®. Austria Pharma Codex, April (2006).
14. Marth E, Kleinhappl B. Albumin is a necessary stabilizer of TBE-vaccine to avoid fever in children after vaccination. Vaccine 20, 532-537 (2001).
15. EMEA, Committee for Human Medicinal Products (CHMP), Note for guidance on the clinical evaluation of vaccines. www.emea.eu.int/CHMP/VEG/164653/05